Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;149(1):104-6.
doi: 10.1001/2013.jamadermatol.467.

Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus

Aileen Y Chang  1 , Elizabeth Ghazi, Joyce Okawa, Victoria P Werth
Affiliations

Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus

Aileen Y Chang et al. JAMA Dermatol. 2013 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Skindex-29 subscale scores for Responders (1A) and Non-responders (1B). Pre- and post-treatment (Tx) Emotions, Functioning, and Symptoms subscale scores shown. Red lines indicate mean score. Black lines connect pre- and post-Tx data for the same individual.
Figure 1
Figure 1
Skindex-29 subscale scores for Responders (1A) and Non-responders (1B). Pre- and post-treatment (Tx) Emotions, Functioning, and Symptoms subscale scores shown. Red lines indicate mean score. Black lines connect pre- and post-Tx data for the same individual.
See this image and copyright information in PMC

References

    1. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64:849–58. - PMC - PubMed
    1. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94. - PMC - PubMed
    1. Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–8. - PMC - PubMed
    1. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433–40. - PubMed
    1. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147:1261–7. - PMC - PubMed

Publication types